Related Experiment Videos
[Ethacizin: pharmacologic properties and prospects for clinical application]
Kardiologiia
|May 1, 1984
Summary
Ethacizine, a new phenothiazine derivative, demonstrates superior antiarrhythmic and antianginal effects compared to ethmozin. This promising drug shows potential for treating coronary heart disease by limiting infarction size.
Area of Science:
- Pharmacology
- Medicinal Chemistry
Context:
- Phenothiazine derivatives are explored for their therapeutic potential.
- Understanding structure-activity relationships is key in drug discovery.
Purpose:
- To investigate ethacizine, a novel phenothiazine derivative, for its pharmacological properties.
- To compare ethacizine's efficacy against its analogue, ethmozin.
Summary:
- Ethacizine exhibits enhanced antiarrhythmic intensity (2x) and duration (4-5x) compared to ethmozin.
- The drug possesses significant antianginal properties, prolonging ST interval elevation inhibition during coronary occlusion.
- Ethacizine increases myocardial ischemia threshold and reduces experimental infarction size.
Impact:
- Ethacizine presents a promising therapeutic agent for managing coronary heart disease.
- Clinical observations support ethacizine's potent antiarrhythmic activity.
- The drug's multifaceted effects offer a novel approach to cardiac treatment.